Novavax AB
Records under this name other than the patents Novavax AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 9 of 9 · Back to Novavax AB
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,729,764 | Iscom Preparation and Use Thereof Term ended Term ended Nov 5, 2026 · Medium confidence | Term ended | Term ended Nov 5, 2026 | Medium confidence |
| US 8,007,806 | Vaccine Composition Comprising a Fibronectin Binding Protein or a Fibronectin Binding Peptide Formerly held Term ended Term ended Nov 1, 2026 · High confidence | Term ended | Term ended Nov 1, 2026 | High confidence |
| US 8,821,881 | Quil a Fraction with Low Toxicity and Use Thereof Term ended Term ended Aug 19, 2026 · High confidence | Term ended | Term ended Aug 19, 2026 | High confidence |
| US 8,187,585 | Vaccine Composition Comprising a Fibronectin Binding Protein or a Fibronectin Binding Peptide Term ended Term ended Jan 20, 2026 · High confidence | Term ended | Term ended Jan 20, 2026 | High confidence |
| US 12,171,828 | Quil a Fraction with Low Toxicity and Use Thereof Term ended Term ended Jul 7, 2024 · High confidence | Term ended | Term ended Jul 7, 2024 | High confidence |
| US 7,838,019 | Composition Comprising Iscom Particles and Live Micro-Organisms Term ended Term ended Jun 29, 2024 · High confidence | Term ended | Term ended Jun 29, 2024 | High confidence |
| US 9,205,147 | Composition Comprising Iscom Particles and Live Micro-Organisms Term ended Term ended Mar 24, 2024 · Medium confidence | Term ended | Term ended Mar 24, 2024 | Medium confidence |
| US 9,901,634 | Compositions Comprising Iscom Particles and Live Micro-Organisms Term ended Term ended Mar 24, 2024 · Medium confidence | Term ended | Term ended Mar 24, 2024 | Medium confidence |
| US 10,813,994 | Composition Comprising Iscom Particles and Live Micro-Organisms Term ended Term ended Mar 24, 2024 · Medium confidence | Term ended | Term ended Mar 24, 2024 | Medium confidence |